The purpose of this study is to assess the reproducibility of hippocampal atrophy rate measurements of commonly used fully-automated algorithms in Alzheimer disease (AD). The reproducibility of hippocampal atrophy rate for FSL/FIRST, AdaBoost, FreeSurfer, MAPS independently and MAPS combined with the boundary shift integral (MAPS-HBSI) were calculated. Back-to-back (BTB) 3D T1-weighted MPRAGE MRI from the Alzheimer's Disease Neuroimaging Initiative (ADNI1) study at baseline and year one were used. Analysis on 3 groups of subjects was performed -562 subjects at 1.5 T, a 75 subject group that also had manual segmentation and 111 subjects at 3 T. A simple and novel statistical test based on the binomial distribution was used that handled outlying data points robustly. Median hippocampal atrophy rates were À 1.1%/year for healthy controls, À 3.0%/year for mildly cognitively impaired and À 5.1%/year for AD subjects. The best reproducibility was observed for MAPS-HBSI (1.3%), while the other methods tested had reproducibilities at least 50% higher at 1.5 T and 3 T which was statistically significant. For a clinical trial, MAPS-HBSI should require less than half the subjects of the other methods tested. All methods had good accuracy versus manual segmentation. The MAPS-HBSI method has substantially better reproducibility than the other methods considered.
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Introduction
A feature of Alzheimer's disease (AD) (Jack et al., 1992 (Jack et al., , 1998 Wang et al., 2003; Evans et al., 2010; Frisoni et al., 2010; Drago et al., 2011 ) is increased hippocampal volume loss when compared to age matched healthy controls (HC). Mildly cognitive impairment (MCI) subjects typically have intermediate hippocampal volumes and rates of loss. Hippocampal atrophy rates have been proposed (Schott et al., 2010; Ard and Edland, 2011) or used (Wilkinson et al., 2012) as end points in clinical trials. Manual segmentation of hippocampi (Barnes et al., 2008; Boccardi et al., 2011 ) is often regarded as the "gold standard" for volume measurement -however this may take about 3 h per MRI scan (Mulder et al., 2014) and requires extensive training. The size of AD clinical trials (typically many hundreds of subjects) means that there is great interest in less labour-intensive methods; as a result several fully automated techniques have been developed and are increasingly used. 
